Originally published in USA Today

By Sanjoy Ghosh

Investors who are interested in the health of their portfolios might wonder how to position themselves for sweeping changes taking place in how health care is done in America: everything from the Affordable Care Act to new efforts to personalize medicine based on a patient’s genetic makeup.

Obamacare, love it or hate it, is in full swing. It’s remaking how health care is done, forcing a new focus on costs and outcomes in ways that are only now becoming fully apparent. Doctors and hospitals are forming new referral networks to manage patient care in new ways, creating winners and losers, as well as some likely consolidation.

Medical care practices are also becoming more digital and data-intensive. They are putting new analytics systems in place to capture and report data on their performances. Adoption of digital record-keeping systems continues to expand, creating new efficiencies. Much of this will give health care some of the productivity benefits that have been seen in other industries as they move online. Of course, patients will also be given better transparency into choices and costs as well, opening up some risks of disruption in a market that has been largely opaque.

And in a move that would provide support and funding for the use of genetic data to prevent and cure diseases, President Obama launched a new Precision Medicine Initiative in his State of the Union address in January. Mapping an individual’s genome has become radically less expensive, allowing for better proactive and personalized treatments.

There is also the long-arc trend of the Baby Boomer population heading for old age, and a tremendous demographic shift with large populations moving into the middle class in the developing world.

Here are some Exchange Traded Funds that can get you some exposure to the trends:

Powershares Dynamic Biotechnology-Genome ETF (PBE): Thomas Yorke, who manages an ETF asset allocation portfolio on Covestor, said he bought PBE because “I wanted the chance to participate in the dynamic biotech sector” and invest in some of the familiar names in biotech, such as Biogen and Amgen. Of course, the ETF has a level of volatility, as does the biotech sector broadly.

Health Care Select Sector SPDR (XLV): This ETF was the second-best performing SPDR ETF in 2014, bested only by utilities, according to ETF Trends. Its top three holdings are Johnson & Johnson, Merck and Pfizer. It also has some exposure to biotech stocks and medical device makers, but offers broader health care exposure than PBE.

Direxion Daily Healthcare Bull 3x Shares (CURE): This is an ETF investors should avoid, as it uses leverage to triple the gains — or the losses — of the underlying index. In this case, CURE tracks the Health Care Select Index, which is the same one tracked by XLV. This ETF has had incredible returns, but can create deep losses as well. As we learned in the last decade, highly leveraged investments are never appropriate for individual investors, so steer clear of CURE.

Sanjoy Ghosh is the chief investment officer for Covestor, an online investing marketplace and registered investment adviser that matches investors with portfolio managers.